MS Speaks
Multiple Sclerosis => TREATMENTS => TYSABRI (natalizumab) => Topic started by: agate on April 27, 2018, 02:23:48 pm
-
From Multiple Sclerosis News Today, April 23, 2018--"#AAN2018: PML Risk Cut by Extending Tysabri Dosing Interval":
https://multiplesclerosisnewstoday.com/2018/04/27/aan2018-pml-risk-cut-by-extending-tysabri-dosing-interval/
-
Another article about this in MedPage Today, May 10, 2018--"Reducing PML risk with natalizumab":
https://www.medpagetoday.com/meetingcoverage/aanposterrounds/72808?xid=nl_mpt_DHE_2018-05-11&eun=g345846d0r&pos=0&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202018-05-11&utm_term=Daily%20Headlines%20-%20Active%20User%20-%20180%20days
-
From Medical News Today, January 7, 2019--"Biogen starts Phase 3B trial to evaluate Tysabri extended interval dosing for RRMS patients." The dosing regimen being studied would involve receiving Tysabri every 6 weeks instead of every 4 weeks.
https://multiplesclerosisnewstoday.com/2019/01/07/phase-3b-trial-tysabri-extended-interval-dosing-rrms/
-
These researchers have found that extended interval dosing of Tysabri (every 5-8 weeks) doesn't reduce the effectiveness of the drug.
From PubMed, February 6, 2020--"Pharmacodynamics of natalizumab extended interval dosing in MS":
https://www.ncbi.nlm.nih.gov/pubmed/32019876
-
Biogen's study comparing Tysabri dosing every 4 weeks with dosing every 6 weeks apparently resulted in an 88% reduction in the risk of contracting PML with the less-frequent dosing:
From Pipeline Review (August 2, 2021), "Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis":
https://bit.ly/37edx03
-
More on this from Neurologylive.com (June 4, 2022), discussing a study presented at the annual CMSC meeting June 1-4, "No Significant Difference in Patient-Reported Outcomes with Natalizumab When Administered Every 6 Weeks":
https://bit.ly/3MmDeNO